



The Australian Group on Antimicrobial Resistance

<http://antimicrobial-resistance.com>

AGAR Progress Report against activity for the period 1 January to 31 July 2022

Prepared 25 July 2022

1. Summary of the last six months
 - a. Sequencing data for 2021 AESOP, ASSOP and GNSOP survey completed
 - b. Final reports for 2021 AESOP, ASSOP and GNSOP surveys will be submitted 29th July 2022
 - c. Three additional institutions confirmed their participation for the 2022 survey
 - Prince of Wales, Sydney, NSW
 - Gosford Hospital, NSW
 - Mater Private Hospital, Townsville, Qld
 - d. Both the Queensland Children's Hospital and Royal Prince Alfred Hospital were able to contribute again in 2022
 - e. AGAR Paediatric group has been formalised
2. Status of Program elements
 - a. Data has been received from 33 laboratories servicing 41 of 53 institutions enrolled in 2022 across Australia, with information on 2,821 records available (Quarter 2 2022 data not due until 12 August 2022)
 - AESOP:
 - 73% of the expected data for Quarter 1 has been received.
 - Of the 107 *E. faecium* received, 80 have been referred for whole genome sequencing.
 - ASSOP:
 - 73% of the expected data for Quarter 1 has been received.
 - Of the 96 Methicillin-resistant *Staphylococcus aureus* received, 76 have been referred for whole genome sequencing.
 - GNSOP:
 - 70% of the expected data for Quarter 1 has been received.
 - Of 1,951 isolates, 225 have been requested for referral for molecular investigation.
3. Issues/challenges
 - a. COVID-19 continues to a significant impact on the participating laboratories operation. Specifically:
 - Cairns Base Hospital confirmed that they are unable to contribute in 2022
 - b. Competing with resources for sequencing resulting in significant delays in receiving data, specifically for GNSOP
 - c. Scheduled meetings
4. Risks

- a. Apart from the issues/challenges raised in item 3, and the risks raised in the project plan the programs should be completed by the scheduled date
5. Financing and resources
During the reporting period, AGAR received \$387,648 (GST excluded) on 28 January 2022 as per the contract with the Department of Health:
6. Next steps
As reflected in the Project Plan provided 07-09-2021 we are on schedule to provide the draft 2021 annual report manuscripts for submission to CDI due 26 August 2022.

Kind regards

A handwritten signature in black ink, appearing to read 'G. Coombs'.

Professor Geoffrey Coombs

Chair, AGAR

President Australian Society for Antimicrobials

E: g.coombs@murdoch.edu.au

On behalf of the AGAR Executive Committee